A PHASE 2, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PROOF OF CONCEPT STUDY TO INVESTIGATE EFFICACY AND SAFETY OF LY4005130 IN ADULT PARTICIPANTS WITH SEVERE ALOPECIA AREATA
- Registry ID
- J5D-MC-FPAC
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- ELI LILLY CANADA INC
- Start date
- 2026-05-26
- Last update
- 2026-04-15
Conditions
Related clinical trials
- A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBI-CONTROLLED, PROOF-OF-CONCEPT TRIAL WITH PART B OPEN-LABEL EXTENSION OF ADX-914 FOR THE TREATMENT OF SEVERE ALOPECIA ARESTA (SIGNAL-AA)
- A PHASE 1B/2A, INTRAINDIVIDUAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF ALD-102 SOLUTION FOR INTRADERMAL INJECTION IN SUBJECTS WITH ALOPECIA AREATA
- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, 3-
ARM, MULTINATIONAL, MULTICENTER, PROOF-OF-CONCEPT STUDY TO EVALUATE THE
EFFICACY AND SAFETY OF AMLITELIMAB MONOTHERAPY BY SUBCUTANEOUS INJECTION IN
ADULT PARTICIPANTS WITH SEVERE ALOPECIA AREATA
- A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED 60-
WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REZPEGALDESLEUKIN IN TREATMENT OF SEVERE TO VERY SEVERE ALOPECIA AREATA IN ADULT PATIENTS (REZOLVE-AA)
- A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PROGRAM TO EVALUATE EFFICACY AND SAFETY OF UPADACITINIB IN ADULT AND ADOLESCENT SUBJECTS WITH SEVERE ALOPECIA AREATA
- A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA
View on source registry